Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

A HTS versus the novel immuno-oncology target HPK1 identifies a range of chemical starting points for the development of potent inhibitors

At Sygnature Discovery, we have recently implemented a new, state-of the-art High Throughput Screening (HTS) system, to complement our existing hit finding capabilities. 

Integrating a HighRes Biosolutions automation platform, Titian Mosaic compound management software and Genedata data processing, the system allows the rapid and robust identification of hits from our custom designed LeadFinder library of 150k compounds.     We demonstrate the capability of this system by describing our robust screening cascade.

The screen has identified several new starting points for HPK1 inhibitor development.

The structures appear to differentiate from those in the reported HPK1 patent literature.

Download Poster

Poster download form with organisation field
Invalid email address provided.
Please only use your business email address.